Omega Therapeutics' epigenomic medicines reduce MYC expression by 55% in early study of cancer patients
Omega Therapeutics, a company designing genetic medicines that dial the output of genes up or down, on Tuesday morning revealed the first data from a clinical trial of its so-called epigenomic controllers.
The treatment represses the notorious MYC gene, which is linked to many cancers but has proven difficult to target. The company tested two doses of its therapy in eight people with hepatocellular carcinoma — the most common form of liver cancer — or other solid tumors where MYC is often a culprit.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.